Abstract
The objective of this study is to assess the effect of anthracyclines/ifosfamide-based adjuvant chemotherapy for soft tissue sarcoma (STS) and provide a relative ranking of regimens for STS. We pooled the hazard ratios of overall survival (OS) and relapse free survival (RFS) by conventional meta-analysis to appraise whether adjuvant chemotherapy benefits STS and performed a network meta-analysis using a Bayesian model to establish the relative ranking of regimens. Nine studies were included in our meta-analysis. The pooled hazard ratios were 0.68 (95%CI: 0.53-0.86) and 0.65 (95%CI: 0.52-0.83) for OS and RFS, respectively. Doxorubicin was indicated as best regimen to benefit OS (probability: 30.2%), while cyclophosphamide + vincristine + doxorubicin + dactinomycin was indicated as the best regimen for RFS (probability: 37.1%). This meta-analysis confirms the positive effect of anthracyclines/ifosfamide-based adjuvant chemotherapy in STS for both OS and RFS.
Keywords:
STS; Soft tissue sarcoma; anthracyclines/ifosfamide-based adjuvant chemotherapy; conventional meta-analysis; network meta-analysis.
MeSH terms
-
Anthracyclines / administration & dosage
-
Anthracyclines / adverse effects
-
Anthracyclines / therapeutic use*
-
Antineoplastic Agents / administration & dosage
-
Antineoplastic Agents / adverse effects
-
Antineoplastic Agents / therapeutic use*
-
Antineoplastic Combined Chemotherapy Protocols / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / adverse effects
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
-
Bayes Theorem
-
Chemotherapy, Adjuvant
-
Cyclophosphamide / administration & dosage
-
Cyclophosphamide / adverse effects
-
Cyclophosphamide / therapeutic use
-
Dactinomycin / administration & dosage
-
Dactinomycin / adverse effects
-
Dactinomycin / therapeutic use
-
Doxorubicin / administration & dosage
-
Doxorubicin / adverse effects
-
Doxorubicin / therapeutic use
-
Humans
-
Ifosfamide / administration & dosage
-
Ifosfamide / adverse effects
-
Ifosfamide / therapeutic use*
-
Neoplasm Recurrence, Local
-
Network Meta-Analysis
-
Sarcoma / drug therapy*
-
Sarcoma / mortality
-
Survival Analysis
-
Vincristine / administration & dosage
-
Vincristine / adverse effects
-
Vincristine / therapeutic use
Substances
-
Anthracyclines
-
Antineoplastic Agents
-
Dactinomycin
-
Vincristine
-
Doxorubicin
-
Cyclophosphamide
-
Ifosfamide